O’Shea JJ, Kontzias A, Yamaoka K et al (2013) Janus kinase inhibitors in autoimmune diseases. Ann Rheum Dis. https://doi.org/10.1136/ANNRHEUMDIS-2012-202576

Article  PubMed  Google Scholar 

Braswell SF, Kostopoulos TC, Ortega-Loayza AG (2015) Pathophysiology of pyoderma gangrenosum (PG): an updated review. J Am Acad Dermatol 73:691–698. https://doi.org/10.1016/J.JAAD.2015.06.021

Article  CAS  PubMed  Google Scholar 

Guma M, Ronacher L, Liu-Bryan R et al (2009) Caspase 1-independent activation of interleukin-1beta in neutrophil-predominant inflammation. Arthritis Rheum 60:3642–3650. https://doi.org/10.1002/ART.24959

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goldburg SR, Strober BE, Payette MJ (2020) Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol 82:1045–1058. https://doi.org/10.1016/J.JAAD.2019.08.090

Article  CAS  PubMed  Google Scholar 

Van Der Zee HH, De Ruiter L, Van Den Broecke DG et al (2011) Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β. Br J Dermatol 164:1292–1298. https://doi.org/10.1111/J.1365-2133.2011.10254.X

Article  PubMed  Google Scholar 

Nikolakis G, Kaleta KP, Vaiopoulos AG et al (2021) Phenotypes and pathophysiology of syndromic hidradenitis suppurativa: different faces of the same disease? A systematic review. Dermatology 237:673–697. https://doi.org/10.1159/000509873

Article  PubMed  Google Scholar 

Kaul A, Gordon C, Crow MK et al (2016) Systemic lupus erythematosus. Nat Rev Dis Prim. https://doi.org/10.1038/NRDP.2016.39

Article  PubMed  Google Scholar 

Yamaoka K (2016) Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 32:29–33. https://doi.org/10.1016/J.CBPA.2016.03.006

Article  CAS  PubMed  Google Scholar 

Clark JD, Flanagan ME, Telliez JB (2014) Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 57:5023–5038. https://doi.org/10.1021/JM401490P

Article  CAS  PubMed  Google Scholar 

Kucharz EJ, Stajszczyk M, Kotulska-Kucharz A et al (2018) Tofacitinib in the treatment of patients with rheumatoid arthritis: position statement of experts of the polish society for rheumatology. Reumatologia 56:203–211. https://doi.org/10.5114/REUM.2018.77971

Article  PubMed  PubMed Central  Google Scholar 

Berekmeri A, Mahmood F, Wittmann M, Helliwell P (2018) Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol 14:719–730. https://doi.org/10.1080/1744666X.2018.1512404

Article  CAS  PubMed  Google Scholar 

D’Amico F, Parigi TL, Fiorino G et al (2019) Tofacitinib in the treatment of ulcerative colitis: efficacy and safety from clinical trials to real-world experience. Therap Adv Gastroenterol. https://doi.org/10.1177/1756284819848631

Article  PubMed  PubMed Central  Google Scholar 

Ruperto N, Brunner HI, Synoverska O et al (2021) Tofacitinib in juvenile idiopathic arthritis: a double-blind, placebo-controlled, withdrawal phase 3 randomised trial. Lancet 398:1984–1996. https://doi.org/10.1016/S0140-6736(21)01255-1

Article  CAS  PubMed  Google Scholar 

Fu Z, He Y, Gao L et al (2023) STAT2/Caspase3 in the diagnosis and treatment of psoriasis. Eur J Clin Invest. https://doi.org/10.1111/ECI.13959

Article  PubMed  Google Scholar 

Loo WJ, Turchin I, Prajapati VH et al (2023) Clinical implications of targeting the JAK-STAT pathway in psoriatic disease: emphasis on the TYK2 pathway. J Cutan Med Surg. https://doi.org/10.1177/12034754221141680

Article  PubMed  Google Scholar 

Kirkegaard T, Edwards J, Tovey S et al (2006) Observer variation in immunohistochemical analysis of protein expression, time for a change? Histopathology 48:787–794. https://doi.org/10.1111/J.1365-2559.2006.02412.X

Article  CAS  PubMed  Google Scholar 

Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76:736–744. https://doi.org/10.1016/J.JAAD.2016.12.005

Article  CAS  PubMed  PubMed Central  Google Scholar 

O’Shea JJ, Murray PJ (2008) Cytokine signaling modules in inflammatory responses. Immunity 28:477–487. https://doi.org/10.1016/J.IMMUNI.2008.03.002

Article  PubMed  PubMed Central  Google Scholar 

De Medeiros AKA, Speeckaert R, Desmet E et al (2016) JAK3 as an emerging target for topical treatment of inflammatory skin diseases. PLoS ONE. https://doi.org/10.1371/JOURNAL.PONE.0164080

Article  PubMed  PubMed Central  Google Scholar 

Sadeghi S, Goodarzi A (2022) Various application of Tofacitinib and Ruxolitinib (Janus kinase inhibitors) in dermatology and rheumatology: a review of current evidence and future perspective. Dermatol Pract Concept. https://doi.org/10.5826/DPC.1204A178

Article  PubMed  PubMed Central  Google Scholar 

Kochar B, Herfarth N, Mamie C et al (2019) Tofacitinib for the treatment of pyoderma gangrenosum. Clin Gastroenterol Hepatol 17:991–993. https://doi.org/10.1016/J.CGH.2018.10.047

Article  PubMed  Google Scholar 

Chang BY, Zhao F, He X et al (2009) JAK3 inhibition significantly attenuates psoriasiform skin inflammation in CD18 mutant PL/J mice. J Immunol 183:2183–2192. https://doi.org/10.4049/JIMMUNOL.0804063

Article  CAS  PubMed  Google Scholar 

Di TT, Ruan ZT, Zhao JX et al (2016) Astilbin inhibits Th17 cell differentiation and ameliorates imiquimod-induced psoriasis-like skin lesions in BALB/c mice via Jak3/Stat3 signaling pathway. Int Immunopharmacol 32:32–38. https://doi.org/10.1016/J.INTIMP.2015.12.035

Article  CAS  PubMed  Google Scholar 

Shi X, Jin L, Dang E et al (2011) IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms. J Invest Dermatol 131:2401–2408. https://doi.org/10.1038/JID.2011.222

Article  CAS  PubMed  Google Scholar 

Witte-Händel E, Wolk K, Tsaousi A et al (2019) The IL-1 pathway is hyperactive in hidradenitis suppurativa and contributes to skin infiltration and destruction. J Invest Dermatol 139:1294–1305. https://doi.org/10.1016/J.JID.2018.11.018

Article  PubMed  Google Scholar 

Schlapbach C, Hänni T, Yawalkar N, Hunger RE (2011) Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 65:790–798. https://doi.org/10.1016/J.JAAD.2010.07.010

Article  CAS  PubMed  Google Scholar 

Solimani F, Meier K, Ghoreschi K (2019) Emerging topical and systemic JAK inhibitors in dermatology. Front Immunol. https://doi.org/10.3389/FIMMU.2019.02847

Article  PubMed  PubMed Central  Google Scholar 

Alavi A, Hamzavi I, Brown K et al (2022) Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol 186:803–813. https://doi.org/10.1111/BJD.20969

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frew JW, Hawkes JE, Krueger JG (2018) A systematic review and critical evaluation of inflammatory cytokine associations in hidradenitis suppurativa [version 1; referees: 2 approved, 1 approved with reservations]. F1000Research. https://doi.org/10.1268/F1000RESEARCH.17267.1

Article  PubMed  PubMed Central